These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36441503)

  • 1. Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint.
    Tripathi A; MacDougall K; Sonpavde GP
    Drugs; 2022 Nov; 82(17):1649-1662. PubMed ID: 36441503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
    Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
    Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
    Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
    Int J Clin Oncol; 2024 Aug; 29(8):1096-1104. PubMed ID: 38850448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Atiq S; Hirshman N; Shariff A; Zhang T
    Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Gupta S; Moon HH; Sridhar SS
    Target Oncol; 2024 Jul; 19(4):483-494. PubMed ID: 38963655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
    Hui G; Stefanoudakis D; Zektser Y; Isaacs DJ; Hannigan C; Pantuck AJ; Drakaki A
    Curr Oncol; 2023 Aug; 30(8):7398-7411. PubMed ID: 37623017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
    Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
    Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review.
    Koshkin VS; Osbourne AS; Grivas P
    Transl Androl Urol; 2021 Oct; 10(10):4022-4035. PubMed ID: 34804845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.